IONS Q3 2023 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$144M-9.7% YoY

Gross Profit

$142M98.5% margin

Operating Income

-$143M-99.3% margin

Net Income

-$147M-102.2% margin

EPS (Diluted)

$-1.03

QoQ Revenue Growth

-23.5%

Cash Flow

Operating Cash Flow

-$109M

Free Cash Flow

-$112M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$2.6B

Stockholders' Equity

$315M

Cash & Equivalents

$352M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$144M	$160M	-9.7%
Gross Profit	$142M	$158M	-10.3%
Operating Income	-$143M	-$59M	-142.2%
Net Income	-$147M	-$47M	-213.7%

Revenue Segments

Commercial

$84M28%

SPINRAZA Royalties

$67M22%

Research and Development Revenue

$60M20%

Collaborative Agreement Revenue

$44M14%

Other Commercial

$17M6%

Eplontersen Joint Development Revenue

$16M5%

Licensing and Other Royalties

$9M3%

Product

$8M3%